Amneal Pharmaceuticals, Inc announced the commercial launch of RELEUKO® (filgrastim-ayow), a biosimilar referencing Neupogen®. RELEUKO® is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. This product was developed in collaboration with Kashiv Biosciences, LLC located in Chicago, Illinois.
source https://www.pharmatutor.org/pharma-news/2022/amneal-launches-second-biosimilar-of-filgrastim-ayow-in-the-us
No comments:
Post a Comment